Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levelsMilan J. Sonneveld, Benjamin Maasoumy, Shao‐Ming Chiu et al.|Journal of Hepatology|2022Cited by 121
Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular RiskEugene Han, Seung Up Kim, Ji Hoe Heo et al.|The American Journal of Gastroenterology|2020Cited by 112
Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)Milan J. Sonneveld, Benjamin Maasoumy, Jun Yong Park et al.|Clinical Gastroenterology and Hepatology|2020Cited by 103
No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populationsHiromi Sawai, Katsushi Tokunaga, Nao Nishida et al.|BMC Medical Genetics|2012Cited by 41
HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral TherapyMilan J. Sonneveld, Benjamin Maasoumy, Shao‐Ming Chiu et al.|Gastroenterology|2023Cited by 23